SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

TLRY is trending following reports that Trump is considering reclassifying marijuana, a move seen as a major catalyst for the cannabis industry. The community is buzzing about potential rallies and short squeezes, with many anticipating significant gains. Discussions also include the potential impact on other cannabis stocks and the broader implications for the sector.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending amid discussions of its recent earnings report and future AI guidance, with the community parsing mixed signals. Despite strong revenue and AI growth, some investors are concerned about margin pressures and the lack of specific long-term forecasts. Analyst upgrades are countered by community members pointing to potential overvaluation and sector rotation.

Jiuzi Holdings, Inc. engages in franchise and operation of retail stores. The firm sells new energy vehicles (NEVs) under the brand name Jiuzi. It operates through the NEVs Sales and Franchise Services segments. The company was founded on October 10, 2019 and is headquartered in Hangzhou, China.

Jiuzi Holdings Inc

Jiuzi Holdings is trending due to news surrounding a significant commitment to expand its private placement to $1 billion, sparking discussion about potential for high gains. However, the community is also wary, with some users labeling the stock a "scam" and expressing concerns about Chinese stocks in general and potential dilution. Some traders are looking at similar stocks, hoping for a related sympathy run.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending due to community discussion around its cancer treatment pipeline, particularly after positive data in prostate cancer trials, leading to speculation about potential partnerships or a buyout. Investors believe the company is undervalued, with a high short interest creating potential for a short squeeze. The community is focused on the upcoming catalysts and continued data releases.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst ($BCRX) is trending as traders discuss the potential impact of the upcoming FDA decision on Orladeyo for pediatric patients, with some anticipating a revenue boost while others believe it's already priced in. Community members are actively debating the stock's valuation, short interest, and the potential for a buyback program to drive the price higher. The acquisition of Astria Therapeutics and the departure of a board member are also being considered as factors influencing the stock's future performance.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi (FRMI) is trending due to a significant stock drop following news of losing its first major tenant for its Texas data center project, sparking discussions about the company's future viability and potential bankruptcy. While some investors believe the sell-off is an overreaction and a buying opportunity, others express concerns about the company's lack of revenue and permits, viewing it as a risky venture amid the AI infrastructure hype. Community sentiment is mixed, with some calling it a scam and others seeing long-term potential if Fermi can secure new tenants and funding.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon's stock is trending after a surprising announcement that CEO Calvin McDonald will step down, coupled with better-than-expected quarterly results. The community is actively discussing the potential implications of this leadership change, along with the company's growth strategy and the impact of tariffs on margins. Investors are also reacting positively to the approval of a $1 billion increase to the stock repurchase program.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as the community rallies around its positive ethos, encouraging each other with the phrase 'We're all gonna make it.' Discussions highlight the strong community, long-term vision, and the potential for significant gains within the Solana meme coin ecosystem. The focus remains on community building and a shared belief in the project's future success.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices surge to new highs, driven by a potential supply squeeze and growing industrial demand, particularly in green technologies and AI. The community is actively discussing the possibility of a sustained breakout, with some anticipating a gamma squeeze and a run to triple-digit prices, while others caution about overbought conditions and potential pullbacks. Discussions also include expectations around shifts in Fed policy and impacts on the dollar.

Katapult Holdings, Inc. is an e-commerce focused financial technology company. The firm is engaged in the provision of e-commerce point-of-sale lease-purchase options for nonprime U.S. consumers. It offers its customers a lease purchase transaction processing system with no long-term obligation and options for ownership. The company was founded in August 2019 and is headquartered in Plano, TX.

Katapult Holdings Inc

KPLT is trending amid discussions about a potential merger and its impact on shareholder value, as well as ongoing speculation around a possible short squeeze. Community members are actively debating the company's value after a proposed all-stock transaction and analyzing its potential for growth. The stock is also experiencing high volatility and unusual trading volume, prompting discussions about potential catalysts and market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail investors on Stocktwits are optimistic about Genius Group’s pivot and hope to see the same returns as MicroStrategy after the latter pivoted to a Bitcoin-first strategy in 2020. | Source: Pixabay

Why Is Genius Group Stock Rising Today?

Genius Group repurchased its stock on the open market at an average price of $0.90 per share from August 28 to September 11, 2025.

Equity

Global Equity ETFs Draw Rising Investor Interest

Global equity funds saw $10.65B inflows as Fed rate cut bets, a weak dollar and diversification needs drive investors abroad.

U.S.-listed shares of Birkenstock Holding were up 3% in premarket trading on Thursday, ahead of the German footwear company's quarterly report before the market opens.Analysts expect its third-quarter revenue to rise 19.3%, similar to the preceding two quarters, according to Kofin data. Investors&nbsp;will be watching for comments on the impact of tariffs, price hikes, supply chain disruptions, and the demand landscape in North America and Europe.Piper Sandler, which reaffirmed its 'Overweight' rating this week, noted that unfavorable foreign exchange rates could pressure the company's reported revenue.Birkenstock, known for its clogs or sandals, is in a notably good position. In May, the company raised its annual profit outlook and authorized a $200 million share buyback. Still,&nbsp;<a href="https://stocktwits.com/symbol/BIRK">BIRK shares</a> are down 11% year-to-date.The stock has gained nearly 6% in the last two sessions, and the latest retail sentiment reading on Stocktwits is ‘extremely bullish,’ signaling investor optimism.<figure class="image"><img style="aspect-ratio:629/72;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_14_at_2_38_43_PM_png_0145047a9b.webp" alt="Screenshot 2025-08-14 at 2.38.43 PM.png" width="629" height="72"><figcaption>BIRK sentiment and message volume as of August 14 | Source: Stocktwits</figcaption></figure>Late last month, Goldman Sachs&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/birkenstock-scores-buy-rating-from-goldman-sachs-shares-rise/choGriXR5vX">raised</a> its rating on Birkenstock to ‘Buy’ from ‘Neutral,’ citing "robust" momentum and an attractive valuation for the company's shares in a challenging&nbsp;macroeconomic backdrop.Footwear companies face broad pressure from U.S. import tariffs on major Asian manufacturing hubs, including China and Vietnam.Swiss company On Holding posted strong quarterly sales and raised its full-year target,&nbsp;attributing the increase to recent price increases on its shoes. In the future, CEO Martin Hoffmann&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/on-holding-ceo-martin-hoffmann-says-the-sportswear-maker-is-in-a-good-position-to-digest-tariffs/chrCS0bRd9p">told</a> Stocktwits that the company is now "in a very good position to digest" the tariffs.Birkenstock also raised prices in the U.S. last month.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Various Birkenstock shoes are displayed on shelves in a Birkenstock store on Ehrenstraße. Photo: Rolf Vennenbernd/dpa (Photo by Rolf Vennenbernd/picture alliance via Getty Images)

Why Are Birkenstock Shares Rising Premarket?

The move shows optimism ahead of the German footwear company's quarterly report.

Birkenstock Holding (BIRK) shares rose over 1.5% in Thursday's session and another 2% in extended trading, after Goldman Sachs raised its rating on the sandal maker.The research firm raised the rating on the company's shares to 'Buy' from 'Neutral,' while maintaining its $60 price target, according to a summary of the investor note on The Fly. That indicates an over 15% upside to BIRK's last closing price.Currently, 20 of the 22 analysts covering the stock have a 'Buy' or higher rating, and two rate it 'Hold,' according to Koyfin data. Their average price target is $72.26.Goldman Sachs sees "robust" momentum and an attractive valuation for Birkenstock in a challenging macro backdrop. The company has a "strong" product proposition, with pricing power and opportunities to win share in a "highly fragmented" footwear market, the research firm said.Goldman Sachs also noted Birkenstock's vertically integrated manufacturing setup in Europe, which would support the company's margins.Although&nbsp;<a href="https://stocktwits.com/symbol/BIRK">BIRK shares</a> have rebounded over the last couple of weeks, they remain 15.5% below their 2025 peak achieved on Jan. 30.On Stocktwits, retail sentiment shifted to 'neutral' early Friday from 'bearish' the previous day, with several users&nbsp;taking note of the latest upgrade.<figure class="image"><img style="aspect-ratio:1416/154;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_25_at_10_41_26_AM_png_d52d1b15f5.webp" alt="Screenshot 2025-07-25 at 10.41.26 AM.png" width="1416" height="154"><figcaption>BIRK sentiment and message volume as of July 25 | Source: Stocktwits</figcaption></figure>In May, Birkenstock raised its annual profit outlook and authorized a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/birkenstock-authorizes-200m-buyback-but-retail-remains-cold/ch0AkaLRbti">$200 million share buyback</a>.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/chinese-e-commerce-giant-jd-com-could-reportedly-snap-up-media-markt-parent-for-2-6-b-retail-bulls-eye-breakout/choGqh1R5v9">Chinese E-Commerce Giant JD.com Could Reportedly Snap Up MediaMarkt Parent For $2.6B: Retail Bulls Eye Breakout</a>

A Birkenstock shoe displayed on in a Birkenstock store in North Rhine-Westphalia, Cologne, Germany. (Photo by Rolf Vennenbernd/picture alliance via Getty Images)

Birkenstock Scores 'Buy' Rating From Goldman Sachs, Shares Rise 

The sandal maker has "robust" momentum, attractive valuation, and pricing power, the research firm says.

German sandal&nbsp;maker Birkenstock has filed an infringement lawsuit in India's capital, New Delhi, against four footwear traders, four factories, and two unnamed individuals following a company investigation revealed the production, sale, and export of counterfeit products, according to a Reuters report.The&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/sustainability/boards-policy-regulation/birkenstock-cracks-down-fakes-india-court-ordered-factory-visits-held-sources-2025-07-06/">report</a>, which cites people familiar with the matter,&nbsp;comes as the footwear industry is garnering increased attention in India. Earlier this month, Crocs (CROX) secured a court nod to pursue a nine-year-old infringement case. At the same time,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/prada-credits-centuries-old-indian-kolhapuri-craftsmanship-behind-open-toe-sandals-design-unveiled-at-milan-show/chmZe7GRReZ">Prada drew criticism</a> after its sandals at a Milan showcase looked nearly identical to Indian Khandasari chappals, prompting the Italian fashion brand to acknowledge the similarity.According to the report, Birkenstock filed the lawsuit in the Delhi High Court in May. It claims that Birkenstock counterfeits were being manufactured in rural areas near the North Indian tourist hub of Agra and sold both locally and exported to other countries. The court has ordered law enforcement inspections of these facilities.India is a key market for the German brand, which last month opened its 50th standalone store in the country,&nbsp;in the financial capital of Mumbai.On Stocktwits, the retail sentiment for BIRK remained 'bullish,' unchanged from a week ago.&nbsp;<a href="https://stocktwits.com/symbol/BIRK">Birkenstock shares</a> are down nearly 14% year-to-date.<figure class="image"><img style="aspect-ratio:615/69;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_07_at_2_06_14_PM_png_bdebef4034.webp" alt="Screenshot 2025-07-07 at 2.06.14 PM.png" width="615" height="69"><figcaption>BIRK sentiment and message volume as of July 7 | Source: Stocktwits</figcaption></figure>The development comes at a time of strength for the company. It recently reported strong results for its fiscal second quarter,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/birkenstock-raises-annual-profit-forecast-shares-retail-sentiment-surge/chivoCURbnc">raised its annual profit forecast</a>, and authorized a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/birkenstock-authorizes-200m-buyback-but-retail-remains-cold/ch0AkaLRbti">$200 million buyback</a>.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Birkenstock Reportedly Sues Indian Footwear Makers Over Counterfeits Amid Rising Industry Scrutiny

India is a key market for the German brand, which last month opened its 50th standalone store in the country.

Nasdaq-listed shares of argenx SE (ARGX) rose 2% by Friday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://argenx.com/news/2024/argenx-announces-european-commission-approval-of-vyvgart--efgart">announced</a> that the European Commission approved its VYVGART 1,000 mg subcutaneous (SC) injection in the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP).CIDP is a rare and often progressive autoimmune disease of the peripheral nervous system. Patients with CIPD experience a range of mobility and sensory issues, including trouble standing from a seated position, pain and fatigue, and frequent tripping or falling.The European Commission approved the subcutaneous injection as a monotherapy for patients with the disease who have received prior treatment with corticosteroids or immunoglobulins.The EC approval will apply to all 27 European Union Member States, as well as to Iceland, Liechtenstein, and Norway.VYVGART for SC injection is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional. The company stated that it is “working closely” with local regulatory authorities to ensure patients can access the treatment as soon as possible.The approval is based on a clinical trial that demonstrated 66.5% of patients treated with VYVGART SC showed evidence of clinical improvement, including improvements in mobility, function, and strength. The study also revealed a 61% reduction in the risk of relapse compared to the placebo.This regulatory approval marks the second for VYVGART SC in Europe, which first received approval as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.On Stocktwits, retail sentiment around argenx remained within ‘bullish’ territory over the past 24 hours while message volume remained ‘normal’.<figure class="image"><img style="aspect-ratio:631/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_20_at_2_09_51_PM_png_2b09c4d552.webp" alt="ARGX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on June 20, 2025 | Source: Stocktwits" width="631" height="68"><figcaption>ARGX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on June 20, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/ARGX">ARGX stock</a> is down by 12% this year but has gained over 40% in the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-considered-perplexity-acquisition-before-14-3-b-scale-ai-deal/chlxqohRRPz">Meta Reportedly Considered Perplexity Acquisition Before $14.3B Scale AI Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an argenx SE logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Argenx Gets European Commission Approval For Drug To Treat Rare Autoimmune Disease, But Stock Fails To Garner Retail Attention

VYVGART for SC injection is available in vials or prefilled syringes and can be administered by a patient, caregiver, or healthcare professional.

U.K.-based biopharmaceutical company GSK plc (GSK) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gsk.com/en-gb/media/press-releases/gsk-s-rsv-vaccine-arexvy-accepted-for-regulatory-review-by-the-european-medicines-agency-to-expand-use-in-adults-18-years-and-older/">said</a> on Friday that the European Medicines Agency (EMA) has accepted its regulatory application to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to include adults aged 18 years or above.Arexvy is already approved in the European Economic Area for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at increased risk for RSV disease due to underlying medical conditions.RSV is a common contagious virus affecting the lungs and breathing passages and impacts an estimated 64 million people of all ages globally every year, GSK said. The virus can aggravate conditions such as asthma and chronic heart failure, leading to hospitalisation and death.The company is looking forward to a decision from the regulator on the application in the first half of 2026.Meanwhile, the firm is continuing to seek an expansion for the treatment scope of its RSV vaccine in geographies including the U.S. and Japan.Arexvy brought in 78 million British pounds ($106.08 million) for GSK in the first quarter of 2025, down 57% from the corresponding period of 2024, following a drop in sales in the U.S., and accounting for just 1% of its overall turnover in the period.On Stocktwits, retail sentiment around GSK remained unmoved within ‘extremely bearish’ territory over the past 24 hours while message volume remained unchanged at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:1258/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_12_12_04_PM_png_f36e4b25b0.webp" alt="GSK's Sentiment Meter and Message Volume as of 12:15 p.m. ET on Jun 13, 2025 | Source: Stocktwits" width="1258" height="126"><figcaption>GSK's Sentiment Meter and Message Volume as of 12:15 p.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure>NYSE-listed shares of GSK are down by 3% as of Friday noon. <a href="https://stocktwits.com/symbol/GSK">The stock</a> is up approximately 22% this year and has increased by about 1% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/urogen-price-target-upgrade-after-fda-approval-for-cancer-medicine/chli4GKRRbJ">UroGen Soars On Price Target Upgrade On Heels Of FDA Approval For Cancer Medicine: Retail Sees Stock Touching $20</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of GSK plc is displayed on a smartphone screen, on April 26, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GSK’s Application To European Authorities For Expanded Use Of RSV Vaccine In Younger Adults Fails To Rejuvenate Retail Optimism

The company is looking forward to a decision from the regulator on the application in the first half of 2026.

Brookfield Asset Management (BAM) has announced a potential investment of up to SEK 95 billion (approximately $10 billion) to develop AI infrastructure in Sweden, marking one of its largest AI initiatives in Europe to date.The funding will be directed toward developing a large-scale AI center in Strängnäs, forming a key component of Sweden’s digital infrastructure aligned with its national AI goals.&nbsp;The facility is expected to grow its capacity from 300 megawatts (MW) to 750 MW, supported by a land deal encompassing around 350,000 square meters.Brookfield expects the Strängnäs facility to create over 1,000 permanent positions, with another 2,000 jobs expected during the 10- to 15-year construction phase.&nbsp;“To compete in the development of AI and realize its economic productivity, it is important to invest at scale in the infrastructure underpinning this technology,” said&nbsp;Head of Europe, Brookfield, Sikander Rashid.According to a Reuters report, the growing adoption of AI and regulations mandating data storage within Europe have sparked a surge in data center development across the region.&nbsp;Companies like Microsoft Inc. (MSFT), Meta Platforms Inc.(META), and Alphabet Inc. (GOOG, GOOGL) have selected Sweden for their facilities, drawn by the country's dependable power supply, infrastructure, and strong connectivity.&nbsp;Brookfield’s AI infrastructure includes more than €100 billion ($114 billion) allocated to areas such as digital connectivity, clean energy, and semiconductor ventures worldwide.&nbsp;In early 2024, the company introduced a €20 billion investment program in France, which features a €10 billion commitment to the country’s inaugural AI manufacturing facility.&nbsp;&nbsp;&nbsp;The New York-based global alternative asset manager oversees over $1 trillion in assets, focusing on long-term investments in real assets and essential service sectors.On Stocktwits, retail sentiment around Brookfield remained in ‘bearish’ territory.<figure class="image"><img style="aspect-ratio:644/74;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_04_083036_png_932e692b08.webp" alt="BAM's Sentiment Meter and Message Volume as of 08:30 a.m. ET on June 4, 2025 | Source: Stocktwits" width="644" height="74"><figcaption>BAM's Sentiment Meter and Message Volume as of 08:30 a.m. ET on June 4, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/BAM">Brookfield</a> stock has gained over 4% year-to-date and over 44% in the last 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/crowdstrike-stock-slumps-post-q1-print-as-analysts-turn-cautious/chkuff6RbwY">CrowdStrike Stock Slumps Post Q1 Print As Analysts Turn Cautious: Retail Seizes Pullback Opportunity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Exchange Rate: 1SEK = 0.10 USD1EUR = 1.14 USD

In this photo illustration, the logo of Brookfield Corporation is displayed on a smartphone screen on April 26, 2025, in Chongqing, China.

Brookfield Commits $10B To Sweden’s AI Expansion: Retail Sees No Reason To Cheer

The AI center in Strängnäs, Sweden, will expand capacity to 750 MW and create 3,000 jobs in the coming years.

German sandals&nbsp;maker Birkenstock Holding (BIRK)&nbsp;said on Wednesday that it plans to buy back $200 million worth of company shares and&nbsp;announced the sale of a block of shares by one of its investors.BK LC Lux MidCo, an entity affiliated with private equity firm L Catterton, is selling 15.7 million shares of Birkenstock at $52.50 a piece. That totals to over $824 million.The shares are being offered to public investors through underwriters in a secondary public offering.Meanwhile, Birkenstock has authorized a $200 million buyback&nbsp;by purchasing an estimated 3.7 million shares. The company's repurchase depends on the progress of the sale by BK LC Lux.Goldman Sachs and JPMorgan are acting as joint book-running managers for the offering.The move comes at a time of strength for the German shoe brand. Earlier this month, Birkenstock reported strong results for the last quarter and raised its annual profit forecast.Revenue rose by a higher-than-expected 19% for its fiscal second quarter, while net profit grew 68%.Birkenstock’s recent performance&nbsp;contrasts with that of other shoe brands, including Nike (NKE) and Crocs, which are grappling with uneven consumer demand following President Donald Trump’s tariff announcements last month.On Stocktwits, the retail sentiment was 'bearish,' unchanged from a month ago.<figure class="image"><img style="aspect-ratio:1276/146;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_29_at_2_30_55_PM_png_e313452594.webp" alt="Screenshot 2025-05-29 at 2.30.55 PM.png" width="1276" height="146"><figcaption>BIRK sentiment and message volume as of May 28 | Source: Stocktwits</figcaption></figure>Birkenstock was listed on the New York Stock Exchange in October 2023.Its shares are down 4.2%% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Birkenstock Authorizes $200M Buyback, But Retail Remains Cold

One of the company's investors is selling over $800 million worth of shares in a secondary market offering.

Shares of Merus N.V. (MRUS) rocketed 32% on Friday morning after the stock witnessed price target hikes on the heels of the company announcing positive data from one of its ongoing drug trials.Oncology company Merus on Thursday <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.merus.nl/news-releases/news-release-details/merus-petosemtamab-pembrolizumab-interim-data-demonstrates">said</a> that the combination of bispecific antibody Petosemtamab with Pembrolizumab demonstrated robust efficacy and durability in its ongoing phase 2 trial as of Feb. 27.Merus CEO Bill Lundberg said the data from the trial demonstrates that Petosemtamab in combination with Pembrolizumab can become “a new standard of care" in head and neck cancer and is “significantly better” than treatment with just Pembrolizumab.The company said that as of Feb. 27, 45 patients had been treated in the phase 2 trial, and the combination was generally well tolerated.The CEO also expressed optimism about sharing data from one or both of its late-stage combination trials in 2026.BofA on Friday hiked the price target on Merus to $92 from $70 while keeping a ‘Buy’ rating on the shares. The firm noted that the recently announced data set the combination as "the best-in-class treatment option for this patient population."The analyst’s new price target implies a 121% upside to Merus’s closing share price of $41.6 on Thursday.BMO Capital also hiked the price target on Merus to $110 from $96 on Friday while keeping an ‘Outperform’ rating on the shares. BMO said it sees a 90% probability of the combination's approval for treating head and neck cancer.On Stocktwits, retail sentiment around Merus jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_23_at_10_48_55_AM_png_3d759215e6.webp" alt="MRUS's Sentiment Meter and Message Volume as of 10:50 a.m. ET on May 23, 2025 | Source: Stocktwits" width="626" height="63"><figcaption>MRUS's Sentiment Meter and Message Volume as of 10:50 a.m. ET on May 23, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/MRUS">MRUS stock</a> is up by about 30% this year and 25% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/jp-morgan-bank-of-america-citigroup-wells-fargo-reportedly-explore-joint-stablecoin/ch0QZ5vRbqs">JPMorgan, Bank of America, Citigroup, Wells Fargo Reportedly Explore Joint Stablecoin</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Merus Stock Soars On Positive Phase 2 Drug Trial Data, Price Target Hikes: Retail’s Thrilled

BofA’s new price target of $92 implies a 121% upside to Merus’s closing share price of $41.6 on Thursday.

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

SPDW
SPDR Portfolio Developed World ex-US ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SPDW News

SPDWSPDR Portfolio Developed World ex-US ETF